Vanderbilt University Medical Center received a $13 million Department of Defense grant to lead a multisite clinical trial that will evaluate repurposed FDA-approved drugs as treatment options for patients with Rett syndrome.

Vanderbilt University Medical Center is partnering with Evergreen Therapeutics Inc. to test whether an Alzheimer’s drug, memantine, can improve cognitive symptoms associated with systemic lupus.

Researchers at Vanderbilt University Medical Center have developed a new method for identifying drugs for the repurposing trials that can lead to new indications for drugs already in use.

Analyzing electronic health records (EHR) of 9,748 patients diagnosed with COVID-19, Cosmin Bejan, PhD, Elizabeth Phillips, MD, and colleagues at Vanderbilt University Medical Center asked whether COVID disease severity correlated with any drugs that happened to be taken by these patients in the months leading up to their diagnosis.

Vanderbilt University Medical Center (VUMC) has been named Data Coordinating Center (DCC) for a nationwide platform of studies aimed at “repurposing” existing drugs to treat mild to moderate symptoms of COVID-19.

Vanderbilt University Medical Center is attracting international attention for its proposal to repurpose existing drugs for new uses in ways that can dramatically improve access to medicines by billions of people throughout the world.